Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen scores a victory for PCSK9, halving cardio risks after one year
Amgen scores a victory for PCSK9, halving cardio risks after one year
Amgen scores a victory for PCSK9, halving cardio risks after one year
Submitted by
admin
on March 16, 2015 - 8:58am
Source:
Fierce Biotech
News Tags:
Amgen
PCSK9 inhibitors
evolocumab
Headline:
Amgen scores a victory for PCSK9, halving cardio risks after one year
Do Not Allow Advertisers to Use My Personal information
